This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain UnitedHealth Group (UNH) Stock
by Zacks Equity Research
UnitedHealth Group (UNH) gains from improved revenues stemming from strong segmental performances, expansion of service offerings and a strong cash balance.
Here's Why You Should Invest in Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) is riding on top-line growth, higher patient volumes, continuous facility expansions and reducing debt levels.
Molina Healthcare (MOH) Misses on Q2 Earnings, Hikes '21 View
by Zacks Equity Research
Molina Healthcare's (MOH) Q2 earnings suffer escalating expenses. However, the same was partly offset by improved revenues and better membership.
Molina (MOH) Q2 Earnings Miss Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of -2.02% and 6.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) second-quarter results are likely to reflect improving revenues stemming from growing patient admissions, partly offset by high costs.
Will Teladoc (TDOC) Q2 Earnings Show Weak Telehealth Demand?
by Zacks Equity Research
Teladoc's (TDOC) Q2 results are likely to reflect a rise in revenues but overall tepid demand as patients started visiting doctors' clinics for in-person checkups.
Molina (MOH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Molina (MOH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anthem's (ANTM) Q2 Earnings Beat Estimates, Decline Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q2 earnings gain from better revenues and growth in Medicaid and Medicare business lines.
Is a Beat in the Cards for Anthem (ANTM) in Q2 Earnings?
by Zacks Equity Research
Anthem's (ANTM) second-quarter results are likely to benefit on the back of higher premiums coupled with growing Medicaid and Medicare membership, partly offset by escalating costs.
Is Molina (MOH) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Molina (MOH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
UnitedHealth (UNH) Beats on Q2 Earnings, Hikes '21 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter 2021 results reflect improving revenues resulting in top-line growth at both the business units, partly offset by higher costs.
Why Should You Add Anthem (ANTM) Stock to Your Portfolio?
by Zacks Equity Research
Aided by high revenues and strong Medicaid and Medicare businesses, Anthem (ANTM) holds enough potential to reap benefits for investors.
Humana (HUM) Joins Montefiore Health for Better Healthcare
by Zacks Equity Research
Humana (HUM) inks a deal with Montefiore Health System to better serve Humana Medicare Advantage members in Bronx, Westchester and Hudson Valley.
Here's Why You Should Add Molina Healthcare (MOH) Stock Now
by Zacks Equity Research
Molina Healthcare (MOH) appears a lucrative investment option at the moment backed by strategic initiatives and healthy revenue stream.
Anthem (ANTM) vs. Humana (HUM): Which is Better-Positioned?
by Zacks Equity Research
Anthem (ANTM) and Humana (HUM) are poised to grow in the thriving insurance brokerage space. Based on certain yardsticks, we try to find out which stock is better than the other.
Here's Why You Should Hold on to Cigna (CI) Stock for Now
by Zacks Equity Research
Cigna (CI) is currently riding on solid top-line growth, expanding global presence and prudent capital deployment.
Acadia Healthcare (ACHC) Forms JV to Serve Southwest Michigan
by Zacks Equity Research
Acadia Healthcare (ACHC) partners with Bronson Healthcare with an aim to provide enhanced behavioral outcomes across Battle Creek, Kalamazoo and the neighboring communities of Michigan.
Molina (MOH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Molina (MOH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Molina Healthcare (MOH): Strong Industry, Solid Earnings Estimate Revisions
by Aditi Saraogi
Molina Healthcare (MOH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Magellan's (MGLN) Unit Ties Up to Boost ASD Patient Outcomes
by Zacks Equity Research
Magellan Health's (MGLN) unit - Magellan Healthcare - collaborated with Invo Healthcare for improving the model that provides ABA treatment to autistic children.
Forget Clover Health (COLV), Buy 3 Non-Meme Healthcare Bets Instead
by Sapna Bagaria
Despite being hotly traded on social-media platforms, Cover Health (CLOV) offers little investment value to long-term investors.
Looking for a Growth Stock? 3 Reasons Why Molina (MOH) is a Solid Choice
by Zacks Equity Research
Molina (MOH) possesses solid growth attributes, which could help it handily outperform the market.
Select Medical's (SEM) Growth Plans to Extend US Footprint
by Zacks Equity Research
Select Medical (SEM) undertakes a series of buyouts and JVs aimed to offer an array of long-term acute care services for treating the U.S. population.
Obamacare Upheld in Recent Rulings: A Boon for Healthcare
by Sapna Bagaria
Insurers and hospital companies are now in conducive regulatory environment with the ACA getting a thumbs up from the Supreme Court.
Molina (MOH) Down 1.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.